Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vejle Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Non-resectable pancreatic cancer
* Biopsy proven adenocarcinoma compatible with pancreatic origin (primary tumor or metastasis)
* If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the pancreas
* Deemed non-resectable at a multidisciplinary conference
Candidate to standard systemic therapy, defined as one of
* Gemcitabine monotherapy,
* Gemcitabine and nab-paclitaxel combination,
* Gemcitabine and capecitabine combination,
* 5-fluorouracil, oxaliplatin and irinotecan combination (FOLFIRINOX), or
* New standard treatments approved by the multidisciplinary cancer group 'Danish Pancreatic Cancer Group' in the inclusion period.
Measurable disease according to RECIST 1.1
ECOG performance status 0-2
Age at least 18 years
Adequate bone marrow, liver and renal function allowing systemic chemotherapy
* Absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l
* Bilirubin ≤ 3 x upper normal value and alanine aminotransferase ≤ 5 x upper normal value
* Calculated or measured renal glomerular filtration rate at least 30 mL/min
Contraception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable
Written and orally informed consent
You may not be if
Potentially resectable disease
* Incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol
* Other active malignant disease requiring therapy
* Other systemic anti-cancer therapy (palliative radiotherapy is allowed)
* Pregnant (positive pregnancy test) or breast feeding women
